Funded Startups in American Fork
Of the eight American Fork entries shown, the largest disclosed round is eLearning Brothers’ $54M on 2022-02-02.
Of the eight American Fork entries shown, the largest disclosed round is eLearning Brothers’ $54M on 2022-02-02. That $54M figure is an outlier relative to the next-largest disclosed amounts in the list: Biolexis Therapeutics at $2M (2026-06-03), Brevium at $1M (2025-08-07), and $500K rounds for Eris Biotech (2024-03-01) and Pronto (2022-05-04). The remaining disclosed amounts (Journeyfront $13M on 2022-01-13) still cluster below eLearning Brothers.
Date-wise, the rounds span from 2022-01-13 (Journeyfront) through 2026-06-03 (Biolexis Therapeutics), with a concentration of earlier 2022 financing: three disclosed rounds appear between 2022-01-13 and 2022-05-04 (Journeyfront $13M, eLearning Brothers $54M, Pronto $500K). The list is heavily weighted toward “Series Unknown” classifications: five of the eight rows show Series Unknown (Biolexis Therapeutics 2026-06-03; Brevium 2025-08-07; Eris Biotech 2024-03-01; Pronto 2022-05-04; plus YouScience and others that explicitly mark Series Unknown), while two rows are marked undisclosed (SponsorCX 2026-05-18; YouScience 2025-04-02).
Most recent rounds
8 shownRelated listings
Frequently asked
What’s the largest disclosed round in the American Fork list, and how far ahead is it of the rest?
eLearning Brothers’ disclosed $54M round on 2022-02-02 is the only disclosed amount above $50M. The next-largest disclosed amounts are Journeyfront’s $13M (2022-01-13) and then $2M for Biolexis Therapeutics (2026-06-03), with $1M (Brevium) and $500K rounds (Eris Biotech and Pronto) trailing further.
Do the rounds cluster in a narrow time window, or are they evenly spread across years?
The eight rows span 2022-01-13 to 2026-06-03, but three of the disclosed rounds fall in early-to-mid 2022: Journeyfront at $13M (2022-01-13), eLearning Brothers at $54M (2022-02-02), and Pronto at $500K (2022-05-04). After that, later years include $500K (Eris Biotech, 2024-03-01) and smaller disclosed rounds such as $1M (Brevium, 2025-08-07) and $2M (Biolexis Therapeutics, 2026-06-03).
How much of the list is missing stage detail, based on ‘Series Unknown’ and ‘undisclosed’?
Five of the eight rows are labeled “Series Unknown” (Biolexis Therapeutics 2026-06-03, Brevium 2025-08-07, Eris Biotech 2024-03-01, YouScience 2025-04-02, and Pronto 2022-05-04). Two rows show “undisclosed” amounts (SponsorCX 2026-05-18 and YouScience 2025-04-02), limiting comparisons across stage and amount for those entries.
Which stage labels appear, and does any single label dominate the disclosed mix?
Beyond “Series Unknown,” the explicit stage labels are relatively sparse: Journeyfront is labeled Series A ($13M on 2022-01-13), SponsorCX is labeled Series A with an undisclosed amount (2026-05-18), and Biolexis Therapeutics and Brevium remain in Series Unknown. Only one entry shows a distinct classification outside that pattern: eLearning Brothers is labeled Private Equity with $54M (2022-02-02).
Are there outliers that suggest unusual sector concentration or unusually large check sizes?
Yes on check size: eLearning Brothers’ $54M (2022-02-02) dwarfs all other disclosed amounts in the list aside from Journeyfront’s $13M. Sector-wise, Health Care appears more than once (Biolexis Therapeutics 2026-06-03; Brevium 2025-08-07), but the most extreme economic outlier is the Private Equity-labeled eLearning Brothers entry in Design ($54M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.